Everything below concerns lactam bridge. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
After absorbing the Lodges around Havana and some other parts of the island, GOCA was recognized as regular and correct by the Supreme Councils of France, England, Scotland, and some other European countries. According to some Masonic historians, however, Cuba and the Antiles was considered illegal. From 1862 to 1868 GOCA established roughly twenty Lodges around the country. de Castro had no luck in absorbing any of the Lodges around Santiago de Cuba, and they remained loyal to the Grand Orient of Colon. Eastern and Western Cuba became increasingly bifurcated in Freemasonry. Despite being the birthplace of Cuban Freemasonry, Oriente Province, and especially Santiago de Cuba, were considered culturally and geographically isolated to the Lodges around Havana. Andrés Cassard and Albert Pike became furious with de Castro. Pike wrote a letter dated November 17, 1865, and accused GOCA of insubordination. He called it "...nothing more than a putrid den of Jacobins." Pike lamented that GOCA was a club more concerned with politics, and not one that upheld the ideals of Freemasonry. In direct opposition to Pike, GOCA published content in which stated that the Southern Jurisdiction was stuck in the dark ages of Old-Testament mysticism. They argued that instead of the Anglo-American motto of Freemasonry, theirs was more closely aligned with the original French Masonic tradition that had once existed in Cuba: Liberty, Equality, Fraternity. They espoused liberalism, declared themselves to be rationalist and Enlightenment thinkers, democratic and anticlerical.
=== 2000–2005 === In 2000, the company acquired Hitech Pathology (Victoria) that merged with Melbourne Pathology. In 2001, Sonic Healthcare acquired Castlereagh Imaging (New South Wales), Castlereagh Imaging Hong Kong (HK), Hunter Imaging Group (New South Wales), Illawarra Radiology Group (New South Wales), Canterbury Medical Imaging (New Zealand), Palmerston North X-Ray (New Zealand), (through Sullivan Nicolaides Pathology) Consultant Pathologists in Townsville (Queensland) and Cairns Pathology Laboratory (Queensland), Queensland X-Ray Group, Illawarra Medical Laboratories (New South Wales), Clinipath Pathology (Western Australia), La Trobe Pathology (Victoria) and Bunbury Pathology (Western Australia) from Foundation Healthcare, and SKG Radiology (Western Australia's largest private diagnostic imaging practice). In 2002, the company acquired The Doctors Laboratory, Britain's largest private pathology practice. Through Sullivan Nicolaides the company acquired the practice of Tom Lynch in Rockhampton (Queensland). Through SKG Radiology, the company acquired Fremantle Radiology (Western Australia). Sonic Healthcare acquired Richard Haskell's NSW Central Coast Pathology practice in 2003, along with the Southside Diagnostic Services Group in Brisbane. In the UK, the company acquired Omnilabs Pathology, merging it into The Doctors Laboratory.
== Selective antagonists == All of the centrally active opioid antagonists used widely in medicine are non-selective, either blocking multiple opioid receptors, or blocking the MOR but activating the KOR. However, for scientific research, selective antagonists are needed which can block one of the opioid receptors but without affecting the others. This has led to the development of antagonists which are highly selective to one of the four receptors:
Sources: en.wikipedia.org
More recently, Blum et al. showed that the muscle spindle firing rate is modeled better as tracking the force of inactive muscle, rather than the length. Furthermore, muscle spindle firing rates show history dependence which cannot be modeled by a linear time-invariant system model.
===== Volumetric method ===== The changing of amount of hydrogen stored in the MOF is measured by detecting the varied pressure of hydrogen at constant volume. The volume of adsorbed hydrogen in the MOF is then calculated by subtracting the volume of hydrogen in free space from the total volume of dosed hydrogen.
On the day that it was inaugurated, two floors were being rented-out to businesses unrelated to Freemasonry. The tenth floor acted as the law offices of the law firm owned by the Grand Master, and to avoid commingling, when he needed to do business as a lawyer, he would sit in his office on the tenth floor, but when he needed to act as the Grand Master, he would walk upstairs to the Office of the Grand Master.
Sources: en.wikipedia.org
In medicine and pharmacology, a trough level or trough concentration (Ctrough) is the concentration reached by a drug immediately before the next dose is administered, often used in therapeutic drug monitoring. The name comes from the idea that on a graph of concentration versus time, the line forms a U-shaped trough at the lowest region, before a new dose sends it higher again. The usual criterion is concentration in the blood serum, although in some instances local concentration within tissues is relevant. It is pharmacokinetically normal that over time, the drug molecules are being metabolized or cleared by the body, so the concentration of drug that remains available is dropping. In a medicine that is administered periodically, the trough level should be measured just before the administration of the next dose in order to avoid overdosing. A trough level is contrasted with a "peak level" (Cmax), which is the highest level of the medicine in the body, and the "average level", which is the mean level over time. It is widely used in clinical trials for newer medicines to investigate therapeutic effectiveness and safety. Ctrough is slightly different from Cmin, the minimum concentration during the time interval between administration of two doses.
=== RAID-FN Inventory === The Ro-Allison-Indiana-Dhurandhar Food Noise Inventory (RAID-FN Inventory) consists of seven items in the short-form version and 23 items in the long-form version. Both versions of the questionnaire capture three distinct factors of food noise: preoccupation with food, persistence of thoughts, and dysphoria arising from those thoughts. A reliability test conducted by the scale’s developers indicated that the food noise construct is likely stable (that is, a trait), although the dysphoric aspect may be a temporary state. Unlike the Food Noise Questionnaire (FNQ), no difference in the level of food noise experienced by men versus women was found using the RAID-FN Inventory. The researchers who developed the RAID-FN Inventory noted that further validation of the tool involving in-person, in-clinic studies is required. Additionally, they suggested that future studies might investigate how the inventory responds to changes in food noise arising from the environment or therapeutic interventions. The direct-to-patient healthcare company Ro provided funding for the RAID-FN Inventory’s development; however, the company had no control over the tool’s creation or the authorship of the validation study.
These reactive oxygen species and their reaction products, such as the hydroxyl radical, are very harmful to cells, as they oxidize proteins and cause mutations in DNA. This cellular damage may contribute to disease and is proposed as one cause of aging. The cytochrome c oxidase complex is highly efficient at reducing oxygen to water, and it releases very few partly reduced intermediates; however small amounts of superoxide anion and peroxide are produced by the electron transport chain. Particularly important is the reduction of coenzyme Q in complex III, as a highly reactive ubisemiquinone free radical is formed as an intermediate in the Q cycle. This unstable species can lead to electron "leakage" when electrons transfer directly to oxygen, forming superoxide. As the production of reactive oxygen species by these proton-pumping complexes is greatest at high membrane potentials, it has been proposed that mitochondria regulate their activity to maintain the membrane potential within a narrow range that balances ATP production against oxidant generation. For instance, oxidants can activate uncoupling proteins that reduce membrane potential. To counteract these reactive oxygen species, cells contain numerous antioxidant systems, including antioxidant vitamins such as vitamin C and vitamin E, and antioxidant enzymes such as superoxide dismutase, catalase, and peroxidases, which detoxify the reactive species, limiting damage to the cell.
The first Soviet development of artillery rockets was in 1921 when the Soviet military sanctioned the Gas Dynamics Laboratory, a small research laboratory to explore solid-fuel rockets, led by Nikolai Tikhomirov, who had begun studying solid and liquid-fueled rockets in 1894, and obtained a patent in 1915 for "self-propelled aerial and water-surface mines. The first test-firing of a solid fuel rocket was carried out in 1928. Further development was carried out in the 1930s by the Group for the Study of Reactive Motion (GIRD), where Soviet rocket pioneers Sergey Korolev, Friedrich Zander, Mikhail Tikhonravov and Leonid Dushkin launched GIRD-X, the first Soviet liquid-fueled rocket in 1933. In 1933 the two design bureaus were combined into the Reactive Scientific Research Institute and produced the RP-318, the USSR's first rocket-powered aircraft and the RS-82 and RS-132 missiles, which became the basis for the Katyusha multiple rocket launcher, During the 1930s Soviet rocket technology was comparable to Germany's, but Joseph Stalin's Great Purge from 1936 to 1938 severely damaged its progress. In 1945 the Soviets captured several key Nazi German A-4 (V-2) rocket production facilities, and also gained the services of some German scientists and engineers related to the project. A-4s were assembled and studied and the experience derived from assembling and launching A4 rockets was directly applied to the Soviet copy, called the R-1, with NII-88 chief designer Sergei Korolev overseeing the R-1's development., The R-1 entered into service in the Soviet Army on 28 November 1950.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.